Log in to your Inderes Free account to see all free content on this page.
Alzinova
1.84 SEK
+10.34 %
Less than 1K followers
ALZ
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Investor consensus
+10.34 %
+24.90 %
+31.14 %
+8.77 %
-46.94 %
-52.92 %
-10.05 %
-63.61 %
-74.40 %
Alzinova is a biotechnology company. The company specializes in the therapeutic treatment of Alzheimer's and conducts research and development of peptides that are further developed as vaccines. In addition, the company also develops various research tools within the field of work. The largest operations are found in the Nordic market. The company was founded in 2011 and has its headquarters in Mölndal.
Read moreMarket cap
191.54M SEK
Turnover
5.71M SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
Revenue M
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
26.2.
2026
Annual report '25
All
Press releases
3rd party
ShowingAll content types
Alzinova enters memorandum of understanding for commercial partnership
Redeye: Alzinova (Q3 review) - Regulatory progress in anticipation of a deal
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio